MWPCG
TGTX icon

Measured Wealth Private Client Group’s TG Therapeutics TGTX Stock Holding History

Measured Wealth Private Client Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-36,235
Closed -$291K – 217
2019
Q1 		$291K Buy
+36,235
New +$196K 0.18% 129

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Measured Wealth Private Client Group's TGTX Position: Q2 2019 in Review

Measured Wealth Private Client Group sold out of TG Therapeutics (TGTX) in Q2 2019, closing a stake of 36,235 shares — an estimated $291K sold.

Measured Wealth Private Client Group first reported a position in TGTX in Q1 2019 and held it in 1 quarter. The position peaked at $291K in Q1 2019. 116 funds tracked by Wall St. Rank hold TGTX as of Q2 2019.

  • Measured Wealth Private Client Group reported no remaining TG Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Measured Wealth Private Client Group sold 36,235 TG Therapeutics shares in Q2 2019, an estimated $291K.
  • Measured Wealth Private Client Group first reported a position in TG Therapeutics in Q1 2019 and held it in 1 quarter.
  • Measured Wealth Private Client Group's TG Therapeutics position peaked at $291K in Q1 2019.
  • 116 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2019.

Based on Measured Wealth Private Client Group's 13F filing for Q2 2019, filed 26 Jul 2019.